Live Breaking News & Updates on Clarus Therapeutics Inc|Page 3
Stay updated with breaking news from Clarus therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Analysts expect Clarus Therapeutics Holdings Inc (NASDAQ:CRXT – Get Rating) to report earnings of ($0.86) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clarus Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($1.13). The firm is scheduled to report its next earnings […] ....
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock. ....
Zacks Investment Research upgraded shares of Clarus Therapeutics (NASDAQ:CRXT – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Monday morning, Zacks.com reports. They currently have $1.75 target price on the stock. According to Zacks, “Clarus Therapeutics Inc. is a specialty pharmaceutical company which provide solutions […] ....
Clarus Therapeutics (NASDAQ:CRXT – Get Rating) had its target price decreased by Needham & Company LLC from $12.00 to $8.00 in a research report report published on Thursday, The Fly reports. Needham & Company LLC currently has a buy rating on the stock. Separately, Zacks Investment Research raised shares of Clarus Therapeutics from a sell […] ....